This Presidential Action establishes a policy to accelerate the research, drug approval process, and access to innovative treatments, specifically psychedelic drugs like ibogaine compounds, for Americans suffering from serious mental illnesses such as major depressive disorder and substance abuse disorder, citing persistent high rates of suicide and inadequate results from standard therapies.

The order directs the FDA to prioritize review via National Priority Vouchers, mandates the establishment of access pathways via the Right to Try Act, allocates HHS funding for State partnerships, directs collaboration between HHS, FDA, and VA for data sharing, and requires the Attorney General to expedite rescheduling reviews for compounds that successfully complete Phase 3 clinical trials.

This Presidential Action addresses the perceived crisis in college sports driven by escalating financial arms races in football and basketball, coupled with inconsistent rules on athlete pay and eligibility resulting from judicial rulings and state legislation.

The order establishes new definitions for 'Improper financial activities' and 'Fraudulent NIL scheme,' and mandates executive agencies to assess compliance with new standards concerning eligibility, transfers, and revenue-sharing for federally funded institutions, effective August 1, 2026.

It strongly encourages Congress to pass legislation while simultaneously directing the Attorney General to challenge conflicting state laws and urging the relevant interstate athletic governing body to adopt specific national standards to protect women's and Olympic sports and ensure institutional financial responsibility.

This Presidential Proclamation directs adjustments to the importation of patented pharmaceuticals and associated active pharmaceutical ingredients (APIs) based on a finding that current import levels threaten national security by creating overreliance on foreign supply chains for critical medications.

The President imposes a 100% ad valorem tariff on these imports, while simultaneously offering reduced rates (20% or 0%) to companies that commit to or achieve onshoring of production and pricing agreements, and grants zero tariffs to certain specialized pharmaceutical categories.

The action also directs federal departments to pursue negotiation agreements to further secure domestic supply and requires monitoring of generic drug imports, though no immediate tariffs are placed on generics.

This presidential action document lists numerous individuals whom the President has nominated to key positions within the Executive Branch and the Federal Judiciary, including appointments to the U.S. Postal Service Board of Governors, ambassadorships, departmental assistant secretary roles, the directorship of the NSF, U.S. Attorney and Marshal posts, and several vacancies on the U.S. District Courts and the U.S. Court of International Trade, all awaiting Senate confirmation.

This document lists a specific nomination sent by the President to the Senate for confirmation: Michael McDonald of the District of Columbia, to serve as Chairperson of the National Endowment for the Humanities for a four-year term, replacing Shelly C. Lowe.

This Presidential Proclamation, issued under Section 232 of the Trade Expansion Act of 1962, addresses the finding that imports of semiconductors, semiconductor manufacturing equipment, and their derivatives threaten U.S. national security due to insufficient domestic production capacity.

The President adopts a two-phase plan, beginning with directing negotiations with foreign jurisdictions while immediately imposing a 25 percent ad valorem tariff on a narrow category of advanced computing chips unless the importation supports U.S. technology supply chain buildout or domestic manufacturing.

The proclamation aims to reduce reliance on foreign supply chains essential for defense and critical infrastructure development.

This Presidential Proclamation announces a finding, based on a report from the Secretary of Commerce under Section 232 of the Trade Expansion Act of 1962, that imports of Processed Critical Minerals and their Derivative Products (PCMDPs) threaten U.S. national security due to excessive foreign reliance, supply chain insecurity, and domestic production decline. The President concurs with the finding and directs the Secretary of Commerce and the United States Trade Representative to jointly negotiate agreements with trading partners to adjust these imports, specifying that if satisfactory agreements are not reached within 180 days, alternative remedies like tariffs or minimum import prices may be considered.

This document provides a compilation of numerous individuals nominated by the President to various high-level federal positions, including roles within executive departments, independent agencies, ambassadorships, and U.S. Attorney offices.

The listings specify the nominee's name, their proposed role, the agency or location, and often denote whether the appointment is to fill an expired term, a vacancy, or a newly created position, detailing the necessary Senate confirmation required for these appointments to take effect.